<?xml version='1.0' encoding='utf-8'?>
<document id="27765537"><sentence text="Aspirin, stroke and drug-drug interactions."><entity charOffset="0-7" id="DDI-PubMed.27765537.s1.e0" text="Aspirin" /></sentence><sentence text="Low-dose aspirin, alone or in combination, is recommended for the secondary prevention of acute non-cardioembolic ischemic stroke and transient ischemic attack, starting soon after the acute event"><entity charOffset="9-16" id="DDI-PubMed.27765537.s2.e0" text="aspirin" /></sentence><sentence text=" Clinically-relevant drug-drug interactions (DDIs) are a major concern of regulatory agencies and practicing physicians" /><sentence text=" Drug's pharmacodynamics and/or pharmacokinetics account for clinically-relevant DDIs that modify efficacy and/or safety of one or more of the co-administered drugs" /><sentence text=" Some non-steroidal anti-inflammatory drugs interact with aspirin pharmacodynamics by competing on the drug target, i"><entity charOffset="58-65" id="DDI-PubMed.27765537.s5.e0" text="aspirin" /></sentence><sentence text="e" /><sentence text=" the platelet's cyclooxygenase-1 protein" /><sentence text=" Although the molecular mechanism(s) of this DDI and its effect on the degree of platelet inhibition in vitro and ex vivo are well unraveled, nevertheless, the extent to which this DDI impacts on long-term antithrombotic efficacy of aspirin in secondary prevention remains unclear"><entity charOffset="233-240" id="DDI-PubMed.27765537.s8.e0" text="aspirin" /></sentence><sentence text=" Aspirin pharmacokinetics does not involve critical cytochrome P450 enzymes nor efflux transporters, therefore clinically-relevant DDIs competing on pharmacokinetic pathways seem unlikely"><entity charOffset="1-8" id="DDI-PubMed.27765537.s9.e0" text="Aspirin" /></sentence><sentence text=" The co-administration of antiplatelet drugs with serotonin storage reuptake inhibitors can create a synergistic effect with antiplatelet agents on platelet inhibition"><entity charOffset="50-59" id="DDI-PubMed.27765537.s10.e0" text="serotonin" /></sentence><sentence text=" Low-dose aspirin, alone or in combination with other antiplatelet agents, remains a cornerstone in treating cerebrovascular disorders"><entity charOffset="10-17" id="DDI-PubMed.27765537.s11.e0" text="aspirin" /></sentence><sentence text=" The relatively straightforward pharmacokinetics of aspirin limits DDIs, giving it a unique advantage over most antiplatelet drugs"><entity charOffset="52-59" id="DDI-PubMed.27765537.s12.e0" text="aspirin" /></sentence><sentence text="" /></document>